Anti-HER2/PD1 bispecific antibody

A bispecific antibody, antibody technology, applied in the direction of antibodies, specific peptides, anti-tumor drugs, etc.
CN111196856AInactive Publication Date: 2020-05-26SUNSHINE GUOJIAN PHARMA (SHANGHAI) CO LTD
1 Cites 10 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SUNSHINE GUOJIAN PHARMA (SHANGHAI) CO LTD
Publication Date
2020-05-26
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the field of tumor treatment, and discloses an anti-HER2 / PD1 bispecific antibody, a preparation method and an application in tumor resistance. Specifically, the single-chain variable fragment scFv and the immunoglobulin antibody IgG are connected through a peptide joint to obtain a bispecific antibody, and the bispecific antibody can target a tumor cell surface molecule HER2 and a T lymphocyte surface molecule PD1. The experimental results show that the bispecific antibody provided by the invention can inhibit the growth of tumor cells, activate T lymphocytes and promote the killing of the T cells to the tumor cells.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of tumor treatment and biotechnology, and relates to a preparation method and application of a bispecific antibody molecule against HER2 and PD1. Background technique

[0002] HER2 (human epidermal growth factor receptor 2), which has receptor tyrosine protein kinase activity, is one of the members of the human epidermal growth factor receptor family, and is only expressed at a low level in a few normal tissues of adults. However, studies have shown that HER2 is overexpressed in a variety of tumors, such as overexpression in about 30% of breast cancer patients and 16% of gastric cancer patients. Overexpression of HER2 in tumors can significantly promote tumor angiogenesis, Tumor growth, and enhanced tumor invasion and metastasis capabilities, are important indicators of poor prognosis in such patients. Therefore, as early as 1998, Herceptin (Genentech / Roche), the first monoclonal antibody drug targeting HER2, was app...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More